Biomedical Research and Therapy: Announcements
Biomedical Research and Therapy (Online ISSN 2198-4093) publishes 12 peer-reviewed issues each year, covering a wide range of biomedical and clinical sciences. Unlike many open-access journals, which charge authors for publication while providing free reader access, Biomedical Research and Therapy does not require fees for subscription, submission, processing, publication, or color image reproduction. Recognized internationally, this journal is committed to disseminating high-quality research in an open-access format, emphasizing basic, translational, and clinical studies on molecular therapeutics and cellular therapies. It includes research involving animal models and clinical trials. The rigorous peer-review process ensures that only scientifically, technically, and ethically sound articles adhering to standard reporting guidelines are published. The journal’s editorial policies are in strict alignment with standards set by the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE), upholding the highest principles of publication ethics. Biomedical Research and Therapy (Online ISSN 2198-4093) is the official journal of the VNUHCM-US Stem Cell Institute, Ho Chi Minh City, Viet Nam. This journal is managed and published by Biomedpress on behalf of the owners, the VNUHCM-US Stem Cell Institute, Ho Chi Minh City, Viet Nam.
News: Important Announcement Regarding Language Editing for Manuscripts from Non-Native English Speakers
<p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Dear Authors, <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">At Biomedpress, we are committed to publishing groundbreaking research that reaches a global audience. To ensure every manuscript meets the highest standards of clarity and scientific communication, we are introducing a new policy to support our international authors. <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Policy Overview: Effective immediately, all manuscripts accepted for revision will require a Certificate of English Editing before final acceptance. This certificate, provided by a professional editing service or a qualified native English-speaking scholar in your field, confirms the manuscript has been polished to a high professional standard. <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Our Goal is Your Success: High-quality language editing minimizes delays in the review process, enhances the readability of your work, and ensures your important findings are presented with the clarity they deserve. <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">How to Comply: <ol style="margin: 16px 0px; padding-left: 18px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;" start="1"> Choose a Service: You may use any reputable English language editing service or a qualified native English-speaking biomedical scholar. Receive Certification: Upon completion, the service or scholar will provide a certificate confirming the editing standard. Submit with Revisions: Please submit this certificate along with your revised manuscript. <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Recommended Service: For your convenience, we have partnered with EditWorld to offer a dedicated editing service with a special discount for Biomedpress authors. While you are free to choose any qualified service, we recommend EditWorld for their proven expertise in biomedical sciences and reliable quality. <blockquote style="border-left: 2px solid #adb2b8; margin: 16px 0px 0px; padding-left: 14px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"> Learn more and claim your discount: https://www.editworld.org <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Final Editorial Check: Please note that all manuscripts will undergo a final language check by our editorial office prior to publication to ensure consistency across the journal. <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">We believe this policy is a valuable investment in the impact and reach of your research. Thank you for your cooperation in maintaining the excellence of our publications. <p class="ds-markdown-paragraph" style="margin: 16px 0px; color: #0f1115; font-family: quote-cjk-patch, Inter, system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif; font-size: 16px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">Sincerely, The Biomedpress Team
News: Important Update: Policy on Use of Artificial Intelligence (AI) in Manuscript Preparation
Biomedpress is committed to upholding the highest standards of research integrity and publishing ethics. To address the evolving use of Artificial Intelligence Generated Content (AIGC) tools, we have updated our policies. All authors submitting manuscripts to any Biomedpress journal must adhere to the following requirements regarding the use of AI tools (such as ChatGPT and other large language models - LLMs): - Mandatory Declaration: Authors must declare the use of any AIGC tools in the development of any portion of their manuscript. This declaration must be placed within the Methods section of the manuscript. - Permitted Use & Restrictions: + The use of AI to generate significant portions of the manuscript content (e.g., results, discussion, conclusions) is strongly discouraged. + AI-generated content is only permissible if it forms part of the formal research design or methods. + Any use of AI-generated content must include a clear description of: (1) The specific content that was AI-generated; (2) The name of the AI model or tool used (e.g., ChatGPT-4, Gemini 1.5, Claude 3 Opus). + AI Cannot Be an Author: AIGC tools cannot fulfill the role of an author under any circumstances and must not be listed as an author on the manuscript. + Review Full Policy: Authors are required to read Biomedpress's comprehensive AI policy, detailed in our Best Practices Guidelines on Research Integrity and Publishing Ethics. + Submission Confirmation: Upon submission, authors are required to confirm that their manuscript adheres to this AI policy. - Action Required for Authors: + Review the full AI policy in the Best Practices Guidelines. + If any AIGC tools were used during manuscript preparation, ensure a declaration is included in the Methods section, detailing the content generated and the tool used. + Never list an AI tool as an author. + Confirm adherence to this policy during the manuscript submission process. These requirements are essential for maintaining transparency, accountability, and trust in the scientific record. Failure to comply may result in delays to the review process or manuscript rejection. We thank you for your cooperation in upholding the integrity of research published in Biomedpress journals. The Biomedpress Editorial Office
News: Biomedpress headquarters relocation
Dear Authors, Reviewers, and Valued Partners, We are pleased to announce an important update regarding Biomedpress: Effective 9 June 2025, our headquarters will relocate to: Phonxay Village, Xaysettha District, Vientiane Capital, Laos Key Details: Operational Continuity: This relocation will not affect our publishing operations, peer-review workflows, manuscript processing timelines, or service quality. Uninterrupted Services: All editorial, review, and publishing activities will continue seamlessly. Contact Information: Email addresses, online submission systems, and digital communication channels remain unchanged. New Official Address: BIOMEDPRESS Phonxay Village, Xaysettha District Vientiane Capital, Laos Email: managingeditor@bmrat.org We remain committed to transparency and excellence in scholarly publishing. Should you have questions about this transition, contact us at managingeditor@bmrat.org. Thank you for your continued trust and collaboration. This strategic move enhances our capacity to serve the global academic community more effectively. Warm regards, Lili Hami BIOMEDPRESS “Elevating Knowledge – Connecting Academia”
News: 2025 Journal Citation Reports released by Clarivate
Clarivate Plc has released the 2025 update to the Journal Citation Reports (JCR), marking the 50th anniversary of the annual reports. The JCR provide a comprehensive resource of high-quality journals, ranked by field to enable academic institutions, researchers and publishers to gauge the significance of journals in the global research landscape. Only journals that have met the quality standards for inclusion in the Web of Science Core Collection are featured within the Journal Citation Reports, to ensure users can rely on the information and descriptive data provided. The annual reports provide an array of publisher-neutral data, metrics, and analysis to enhance user understanding of journal performance, including the widely recognised Journal Impact Factor (JIF) and the Journal Citation Indicator. This year’s release has a strong focus on research integrity, in order to provide a robust tool to assess the trustworthiness and impact of global leading academic journals. Key highlights of the 2025 Journal Citation Reports The JCR includes data from a total of 22,249 journals across 254 categories Over 6,200 of these were published via gold open access Scholarly journals from 111 countries are recognised and receive a JIF, including 14,591 in the sciences and 7,559 in the social sciences, as well as 3,368 journals in the arts and humanities 618 journals receive a JIF for the first time This years’ release excludes citations to and from retracted content when calculating the JIF numerator, ensuring that citations from retracted articles do not contribute to the numerical value of the JIF. However, retracted articles will still be included in the article count (JIF denominator), maintaining transparency and accountability. This policy affects 1% of journals. Nandita Quaderi, Senior Vice President & Editor-in-Chief, Web of Science, Clarivate, said: “We are proud to remain true to our heritage while adapting to changes in the scholarly landscape. As we celebrate the 50th anniversary of the JCR, we are embracing our founder Eugene Garfield’s vision and looking to the future, reinforcing our dedication to maintaining the integrity of the scientific record and continuing our journey towards a more equitable, transparent and trustworthy scholarly ecosystem.” Emmanuel Thiveaud, Senior Vice President, Research and Analytics, Academia & Government at Clarivate said: “We are excited to present the 2025 edition of the Journal Citation Reports, which continues to serve as a vital tool for the global research community. These valuable data and insights empower researchers and institutions to make informed decisions, fostering the advancement of knowledge and innovation.” Nandita Quaderi celebrates 50 years of Journal Citation Reports, and digs deep into the newly launched 2025 edition
News: Journal Citation Reports 2025: Addressing retractions and strengthening research integrity
From 2025 (2024 data), citations to and from retracted articles will no longer contribute towards the Journal Impact Factor. Ever since scientists began to communicate the results of their work, they have had to revise and correct their findings, with the first retraction recorded as early as 1756. Articles are retracted for many reasons – ranging from honest mistakes to intentional manipulation – but whatever the reason, retractions play a crucial role in maintaining the integrity of the scholarly record. They serve as a mechanism for self-correction, ensuring that erroneous or fraudulent results or conclusions do not mislead the public, the scientific community or policy makers – creating an unsound foundation for future discoveries, policies or behavior. Journal Impact Factor as a marker of trust We make every effort to ensure that only trustworthy journals are indexed in the Web of Science Core Collection, the data source for the Journal Citation Reports (JCR). However, even trustworthy journals sometimes publish content that goes on to be retracted, and we have been diligently flagging retracted articles in indexed journals since 2016 and incorporating Retraction Watch data since 2022. Our commitment to research integrity is not limited to our robust editorial selection and introducing new features in the Web of Science; it extends to the metrics, indicators and visualizations we include in the JCR and the insights we publish in our Institute for Scientific Information (ISI) reports. We have been suppressing the Journal Impact Factor (JIF) for journals in which we observe signs of anomalous citation behaviour since the 2008 release. In 2023, we extended the JIF from only the most impactful journals in the sciences and social sciences to all journals that have passed our <a href="https://clarivate.com/academia-government/scientific-and-academic-research/research-discovery-and-referencing/web-of-science/web-of-science-core-collection/editorial-selection-process/journal-evaluation-process-selection-criteria/?campaignname=JCR_Launch_Retention_AG_RA_Global_2025&campaignid=701QO00000avg0zYAA&utm_campaign=JCR_Launch_Retention_AG_RA_Global_2025&utm_source=Blog&utm_medium=Owned_Press&utm_content=&utm_term=blog1">quality criteria and are indexed in the Web of Science Core Collection. In doing so, we have evolved the JIF from a journal-level marker of scholarly impact in the sciences and social sciences to a marker of both impact and trustworthiness across all disciplines. In 2024, we introduced new unified rankings across our science and social science subject categories, sending another strong signal that journal quality should be equated with trustworthiness rather than high citation impact. Retracted content and citations Citations to and from retracted content need to be treated with caution. Currently, retracted articles represent only a tiny fraction of the scholarly record; in the Web of Science Core Collection, retracted content represents just 0.04% of indexed content. However, it is worth noting that from first investigation by the publisher, to sign off from multiple authors and their institutions, and sometimes even legal challenges, retractions typically take years rather than months. This combination of low volumes and long lead times for retractions means that citations to and from retracted articles represent a tiny contribution to JIF calculations. Overall, of the 4.6+ million citations that contributed to the JIF across ~ 22,000 journals in the 2024 JCR release, only ~20,000 were to or from content that had been retracted at that time (~0.4%). (See here for more information on how the JIF is calculated). In recent years there has been an increase in the number of retractions and we have also noted signs of a reduction in the time it takes to retract indexed articles. Given these trends, we have decided to introduce a new policy to pre-emptively guard against any such time that citations to and from retracted content could contribute to widespread distortions in the JIF. Starting from this year’s JCR release, we will exclude citations to and from retracted content when calculating the JIF numerator, ensuring that citations from retracted articles do not contribute to the numerical value of the JIF. However, retracted articles will still be included in the article count (JIF denominator), maintaining transparency and accountability. True to our heritage, leading through change All those involved in creating, reviewing, publishing and assessing academic literature share the responsibility for protecting the integrity of the scholarly record, and we take our part in that collective responsibility very seriously. This change is just the latest step in our ongoing efforts to support research integrity across editorial selection, our products and our metrics. As we move forward, we will continue to monitor changes in journal behavior, consider community feedback, and examine how we might improve other indicators, descriptive data and visualizations contained within the JCR. We are proud to remain true to our heritage while adapting to changes in the scholarly landscape. Eugene Garfield, creator of the Science Citation Index in 1975 – the world’s first citation index and the predecessor of the Web of Science – is best known as a pioneer in bibliometrics, but he also played an important part in shaping thinking around research integrity and ethics in scientific publication. As we celebrate the 50th anniversary of the JCR, we are embracing Garfield’s vision and looking to the future, reinforcing our dedication to maintaining the integrity of the scientific record and continuing our journey towards a more transparent, trustworthy and robust scholarly ecosystem. Explore all our blogs about Journal Citation Reports. https://clarivate.com/academia-government/blog/journal-citation-reports-2025-addressing-retractions-and-strengthening-research-integrity/ Dr Nandita Quaderi Senior Vice President & Editor-in-Chief, Web of Science (This document is copied from https://clarivate.com)
Biomedpress has begun depositing its digital content in the Portico archive since July 2024, to guarantee long-term digital preservation of its Open Access e-journals. Portico is a community-supported digital preservation service for electronic journals, e-books and other digital academic content. Portico provides libraries and publishers with reliable preservation of electronic resources, and contributes expertise and technical assistance to national libraries, ensuring that their content will be accessible to researchers, scholars, and students in the future. Portico focuses on the long-term management of stored content. When online academic content was no longer hosted or available, Portico saw it as a "trigger event". For subscription journals, more than 1,000 participating libraries in Portico will be granted access if trigger events occur; for Open Access journals, content will be provided to everyone free of charge.
News: Clarivate Journal Citation Reports 2024
Clarivate Plc has released the 2024 update to the Journal Citation Reports (JCR). The reports provide a comprehensive resource of high-quality journals, ranked by field to enable academic institutions, researchers and publishers to gauge the significance of journals in the global research landscape. Changes to journal rankings include the addition of the Emerging Sources Citation Index. Only journals that have met the rigorous quality standards for inclusion in the Web of Science Core Collection are featured within the Journal Citation Reports, to ensure that users can confidently rely on the information and descriptive data provided. The annual reports provide a rich array of publisher–independent data, metrics and analysis to enhance user understanding of journal performance, including the widely recognised Journal Impact Factor (JIF) and the Journal Citation Indicator. This year, for the first time, the JCR includes unified rankings across subject categories. There will no longer be separate JIF rankings for the nine subject categories that are indexed in multiple editions. Now those journals will receive a single ranking in their subject category, and the separate rankings will be eliminated. For example, a psychiatry journal listed in SCIE and SSCI will now be ranked in one unified Psychiatry ranking rather than two. Clarivate's Journal Citation Reports continue to evolve, writes Nandita Quaderi Key highlights for the 2024 release: The JCR has been enhanced to provide an easier and more complete user experience. It includes the integration of journals from the Emerging Sources Citation Index (ESCI) in the new unified category rankings. Coverage of more than 21,800 journals – including ~5,800 journals which publish all their content via open access. Scholarly journals from 113 countries, across 254 categories are recognized and receive a JIF. This includes 14,090 science journals, 7,321 social science journals and 3,304 arts & humanities journals. 544 journals receive a Journal Impact Factor for the first time. Dr. Nandita Quaderi, Senior Vice President & Editor-in-Chief, Web of Science, Clarivate, said: “The creation of unified rankings is part of a series of policy changes we have made to support research integrity and help level the global playing field by making the JIF a marker of trust as well as scholarly impact. Last year we extended the JIF to include ESCI journals. This year by ranking ESCI journals alongside all other journals in the same subject category we are sending another strong signal that all trustworthy journals – including newer journals and those with a niche or regional focus – should be valued and given consideration, regardless of how highly cited they are.” Emmanuel Thiveaud, Senior Vice President, Research and Analytics, Academia & Government at Clarivate, added: “For nearly half a century, the global research community has relied on the annual Journal Citation Reports to confidently identify leading and trusted journals in their fields. This year’s enhancements are designed to address the evolving needs of our customers and the unified rankings across subject categories will enhance their ability to evaluate the performance of journals.” To explore all available data, metrics and analysis visit the Journal Citation Reports.
Call for: Free to publish in a Web of Science and Scopus indexed journal
Biomedical Research and Therapy - a prestigious open-access journal that serves as a beacon of excellence in the field of biomedical research and therapy. As a leading publication in the field, we are dedicated to fostering innovation and exploration in medicine by providing a platform for researchers, clinicians, and scientists to share their groundbreaking findings with the global scientific community. Publishing with Biomedical Research and Therapy offers a myriad of benefits. Firstly, our open-access policy means that your research will be freely available to readers worldwide, maximizing the impact of your work and facilitating knowledge dissemination. Furthermore, being indexed in reputable databases such as Web of Science and Scopus enhances the visibility and credibility of your research, ensuring that it reaches a wide audience of peers, collaborators, and potential funders. Moreover, our journal boasts a rigorous peer-review process that upholds the highest standards of scientific integrity and quality. By publishing with us, you can be confident that your work will undergo thorough evaluation by experts in the field, providing valuable feedback and enhancing the robustness of your research. Additionally, our journal offers a swift and efficient publication process, enabling researchers to disseminate their findings in a timely manner. Whether you are a seasoned researcher or an early-career scientist, Biomedical Research and Therapy provides a platform for you to showcase your work and contribute to the advancement of medicine. Join us in our mission to advance healthcare through cutting-edge research and transformative therapies. Submit your manuscript to Biomedical Research and Therapy and become part of a vibrant community of scholars dedicated to pushing the boundaries of biomedical science.
Biomedical Research and Therapy journal has been accepted for indexing in the Scopus database
I am pleased to inform you that Biomedical Research and Therapy journal has been accepted for indexing in the Scopus database (by Elsevier). This indexing will provide a great opportunity for the journal to disseminate high-quality works to readers worldwide. https://suggestor.step.scopus.com/progressTracker/?trackingID=64D6EBEC0D8B342C Scopus is a large and reputable online journal database managed by Elsevier. It provides information on scientific articles, books, journals, and conferences in various fields including natural sciences, engineering, social sciences, medicine, and arts. Scopus has a strict peer-review mechanism for over 22,000 scientific journals from more than 5,000 publishers worldwide. This database provides information on the citation count of articles, impact factor, and h-index of authors, helping researchers to evaluate and track the development of research in their field. Moreover, Scopus also offers data analysis tools and graphs to help users understand and analyze scientific information easily and effectively. It is a useful tool for researchers, teachers, students, and research organizations to access and monitor the latest research trends.
News: 2024 Journal Citation Reports: Changes in Journal Impact Factor category rankings to enhance transparency and inclusivity
New – unified rankings for each of our 229 science and social science categories; no Journal Impact Factor (JIF)™ rankings for the arts and humanities categories The scholarly landscape is witnessing a significant increase in both the quantity and sophistication of fraudulent behaviors, posing a substantial threat to the integrity of the scholarly record. At Clarivate™, we have an unwavering commitment to safeguard the integrity of the scholarly record and recognize a pressing need for indicators of trustworthiness at the journal level. Over the past few years, we have implemented a series of policy changes for the Journal Citation Reports (JCR)™ aimed at aligning coverage between the Web of Science Core Collection™ and the JCR, providing more transparency of the data underlying JCR metrics encouraging a more inclusive, more holistic way of comparing journals. Recent changes to the JCR have included the addition of profile pages for journals indexed in the Arts & Humanities Citation Index (AHCI)™ and Emerging Sources Citation Index (EHCI)™ and the introduction of the Journal Citation Indicator (JCI) in 2021. The JCI is field-normalized to facilitate the comparison of journals across different disciplines, including the arts and humanities. We also extended the Journal Impact Factor (JIF)™ to AHCI and ESCI journals in 2023 so that it now encompasses all quality journals in the Web of Science Core Collection. This inclusive approach resulted in more than 9,000 journals from more than 3,000 publishers benefiting from more data, additional data visualizations and greater transparency added to their JCR profiles. This set of journals includes recently launched journals, open access journals, those with a niche or regionally focused scope, and journals from the Global South. In making these changes, we have evolved the JIF from an indicator of scholarly impact (the numerical value of the JIF) in the sciences and social sciences to an indicator of both scholarly impact and trustworthiness (having a JIF – regardless of the number) across all disciplines at the journal level. In 2023, we also changed the way the JIF is displayed – transitioning from three decimal places to one. This is important as it created more ties in JIF rankings to encourage consideration of additional indicators and descriptive factors alongside the JIF when comparing journals. Our commitment to enhancing transparency and trust continues in the forthcoming JCR release in June 2024. Two notable changes, which we announced last year, will be implemented in the JIF category rankings. We will move from edition-specific category JIF rankings to unified rankings for each of our 229 science and social science categories. We will no longer provide separate JIF rankings for the nine subject categories that are indexed in multiple editions. For example, the Psychiatry category is included in both Science Citation Index – Expanded (SCIE)™ and Social Sciences Citation Index (SSCI)™ and we currently publish a separate Psychiatry ranking for each edition. We will replace these separate rankings with a single, unified ranking. Additionally, the new unified rankings will include journals indexed in ESCI. Using Psychiatry once again as our example – we will display a single Psychiatry ranking that includes journals indexed in SCIE, SSCI and ESCI. The creation of combined category rankings will provide a simpler and more complete category view for the evaluation of journal performance. Typically, ESCI journals have lower JIFs than SCIE, SSCI or AHCI journals in the same category. This is because entry into SCIE, SSCI and AHCI requires an additional step; a journal needs to pass our four impact criteria – designed to select journals with the highest scholarly impact – in addition to the 24 quality criteria that select for editorial rigor and best publishing practice. However, we know there are some ESCI journals with a higher JIF than SCIE, SSCI or AHCI journals in the same category. There are a couple of reasons for this. Firstly, the differentiator between ESCI and SCIE/SSCI/AHCI isn’t just a journal’s JIF at a given moment in time – it is dependent on whether a journal passes our four impact criteria. Secondly, we have paused impact evaluations since 2022 to focus our efforts on quality evaluations of submitted and indexed journals. This was an informed and deliberate decision driven by the increased effort needed to keep Web of Science free of compromised content and supported by the fact that ESCI journals now also have a JIF and from June will be included in the existing science and social science JIF category rankings. We will not introduce JIF rankings for the arts and humanities categories It was our intention to also introduce rankings for the 25 unique arts and humanities-specific categories this year. However, we have re-evaluated this decision following extensive data analysis and consultations with the scholarly community. There is considerable variance in average citation speed and volume between disciplines. In general, citations in the arts and humanities are far lower and slower than citations in the sciences or social sciences. In-depth modeling of JCR data revealed that introducing JIF rankings for the arts and humanities categories would create multiple, very large ties in rank. This in turn would create very skewed quartile distributions, including instances where certain quartiles would be entirely absent from a category. We shared our findings with a variety of stakeholders from across the scholarly community and found consensus that the introduction of JIF rankings for our 25 unique arts and humanities-specific categories would be difficult to interpret and of questionable value. The most appropriate way to compare and rank journals in the arts and humanities categories is through the JCI and JCI rankings introduced in 2021. We remain deeply committed to providing trustworthy data and responsible metrics and therefore have made the decision not to introduce JIF rankings for the arts and humanities categories in this year’s JCR release. This is the first in a series of updates on the 2024 JCR. Bookmark this page and stay tuned for further updates. Listen to Dr. Nandita Quaderi’s interview on the CCC’s Velocity of Content podcast to hear more details about these changes to the 2024 Journal Citation Reports. https://clarivate.com/blog/2024-journal-citation-reports-changes-in-journal-impact-factor-category-rankings-to-enhance-transparency-and-inclusivity/
News: Biomedical Research and Therapy receives its first impact factor of 0.8 (Q3)
We are pleased to share that Biomedical Research and Therapy (ISSN: 2198-4093) has received its first Impact Factor of 0.8 (Q3) in the Journal Citation Reports? (Clarivate) in June 2023. Biomedical Research and Therapy continues to be indexed in the Emerging Sources Citation Index (ESCI) within the Web of Science Core Collection. This is the first time that Clarivate has awarded Impact Factors to journals outside of the core flagship indices, SCIE and SSCI, creating greater transparency around the citedness of ESCI-indexed journals. The 2022 Journal Impact Factor is calculated by dividing the number of citations of publications in a journal in the Web of Science records in 2022 by the number of citable publications published in the journal in 2020 and 2021. The journal?s performance is inseparable from the support and dedication of all journal editors, reviewers, authors, and readers. We would like to take this opportunity to thank all of you who have contributed to the journal.
Call for: Call for editors of Biomedical Research and Therapy
Biomedical Research and Therapy seeks applications from enthusiastic researchers and scholars who can oversee and maintain the editorial direction of the journal to ensure a steady flow of engaging and thought-provoking original research publications. Biomedical Research and Therapy publishes 12 peer-reviewed issues per year in all fields of biomedical and clinical sciences for internationally diverse authorship. Unlike most open access journals, which are free to readers but not authors, Biomedical Research and Therapy does not charge for subscription, submission, processing, or publication of manuscripts, nor for color reproduction of photographs. An international peer-reviewed journal, it publishes high quality open access research articles with a special emphasis on basic, translational and clinical research into molecular therapeutics and cellular therapies, including animal models and clinical trials. The peer-review process will only accept content that is scientifically, technically and ethically sound, and in compliance with standard reporting guidelines. Biomedical Research and Therapy’s Editorial Policies follow the recommendations of the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE) for guidance on policies and procedures related to publication ethics. The journal is indexed and abstracted by ESCI (Web of Science, Clarivate Analytics). Journal Citation Indicator (2020): 0.16 If you are interested in becoming an editor for Biomedical Research and Therapy, please fill the form here. Posted by Biomedpress 30/8/2021
News: Aims & Scope of Biomedical Research and Therapy updated
Dear Authors and Readers, Biomedical Research and Therapy (ISSN 2198-4093) was published by Springer in Global Science Journals from 2014-2015, and BioMedPress from 2016 to now. As a result of a revolution, and to improve the journal quality, the publisher decided to revise the aims and scope of Biomedical Research and Therapy. From October 2020 (Issue 10, Vol 7), Biomedical Research and Therapy will focus on biomedicine that publishes high-quality open access research articles with a special emphasis on basic, translational and clinical research into molecular therapeutics and cellular therapies, including animal models and clinical trials. Original research ranges from new concepts in human biology and disease pathogenesis to robust preclinical bases for new therapeutic modalities and drug development to all phases of clinical work and innovative technologies aimed at improving human health. Current areas of interest also include: Gene and cell therapies Clinical genomics Regenerative medicine High-definition medicine Effects of the environment in human health Artificial intelligence in health care Early disease diagnosis Microbiome Aging The peer-review process will only accept content that is scientifically, technically, and ethically sound, and in compliance with standard reporting guidelines. Please read the Aims and Scope here. Best wishes, Lili Hami Journal Manager, Biomedical Research and Therapy Biomedpress, Ho Chi Minh city, Viet Nam
Call for: Ready to submit your next paper?
Biomedical Research and Therapy is calling for manuscripts Could your research be a good fit for the journal? Find out how you can benefit from publishing with us. Download flyer at here: Call for paper BMRAT
News: Biomedical Research and Therapy uses new output style for references
From Issue 4, Vol 5 (2018), BMRAT uses the reference style of VANCOUVER style. You should use reference manager software such as Endnote during the manuscript preparation. And then format reference with Vancouver style. Vancouver is a numbered referencing style commonly used in medicine and science, and consists of: citations to someone else's work in the text, indicated by the use of a number a sequentially numbered reference list at the end of the document providing full details of the corresponding in-text reference It follows rules established by the International committee of Medical Journal Editors, now maintained by the U.S. National Library of Medicine. It is also known as Uniform Requirements for Manuscripts submitted to Biomedical Journals. For examples: O'Campo P, Dunn JR, editors. Rethinking social epidemiology: towards a science of change. Dordrecht: Springer; 2012. 348 p. Schiraldi GR. Post-traumatic stress disorder sourcebook: a guide to healing, recovery, and growth [Internet]. New York: McGraw-Hill; 2000 [cited 2006 Nov 6]. 446 p. Available from: http://books.mcgraw-hill.com/getbook.php?isbn=0071393722&template=#toc DOI: 10.1036/0737302658 Halpen-Felsher BL, Morrell HE. Preventing and reducing tobacco use. In: Berlan ED, Bravender T, editors. Adolescent medicine today: a guide to caring for the adolescent patient [Internet]. Singapore: World Scientific Publishing Co.; 2012 [cited 2012 Nov 3]. Chapter 18. Available from: http://www.worldscientific.com/doi/pdf/​10.1142/9789814324496_0018 Stockhausen L, Turale S. An explorative study of Australian nursing scholars and contemporary scholarship. J Nurs Scholarsh [Internet]. 2011 Mar [cited 2013 Feb 19];43(1):89-96. Available from: http://search.proquest.com.ezproxy.lib.monash.edu.au/docview/858241255?accountid=12528 Kanneganti P, Harris JD, Brophy RH, Carey JL, Lattermann C, Flanigan DC. The effect of smoking on ligament and cartilage surgery in the knee: a systematic review. Am J Sports Med [Internet]. 2012 Dec [cited 2013 Feb 19];40(12):2872-8. Available from: http://ajs.sagepub.com/content/40/12/2872 DOI: 10.1177/0363546512458223 Subbarao M. Tough cases in carotid stenting [DVD]. Woodbury (CT): Cine-Med, Inc.; 2003. 1 DVD: sound, color, 4 3/4 in. Stem cells in the brain [television broadcast]. Catalyst. Sydney: ABC; 2009 Jun 25.
Call for: Biomedical Research and Therapy journal invites proposals for special issues
The Biomedical Research and Therapy invites proposals for special issues, especially on the following themes: - Cells based therapies for cancers - Targeting therapy - Nanomedicine Proposals for Special Issues should be submitted by the Lead Guest Editor of the Special Issue and should include the following: - The journal for which the Special Issue is intended - A suggested title for the Special Issue (should not exceed 10 words) - Proposed Aims and Scope, giving an overview of the Special Issue’s intended focus and a list of the topics to be covered - A list of Guest Editors who will join the Lead Guest Editor in managing the Special Issue, including their names, emails, affiliations, and a short biography (one paragraph) of each of the Guest Editors Special Issue proposals are welcome at any time during the year, and should be submitted to managingeditor@bmrat.org. OR Online Submission at here Please read more information at here.